Expert Review of Neurotherapeutics最新文献_第5页

An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder. 利培酮治疗精神分裂症和双相情感障碍的现有和新兴长效制剂概述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1080/14737175.2024.2370349

Justin Faden, Camila Ramirez, Vanessa Martinez, Leslie Citrome

{"title":"An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder.","authors":"Justin Faden, Camila Ramirez, Vanessa Martinez, Leslie Citrome","doi":"10.1080/14737175.2024.2370349","DOIUrl":"10.1080/14737175.2024.2370349","url":null,"abstract":"Introduction: Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations.Areas covered: This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another.Expert opinion: There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"761-771"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distinguishing essential tremor from Parkinson's disease: clinical and experimental tools. 区分本质性震颤和帕金森病：临床和实验工具。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1080/14737175.2024.2372339

Luca Angelini, Giulia Paparella, Matteo Bologna

{"title":"Distinguishing essential tremor from Parkinson's disease: clinical and experimental tools.","authors":"Luca Angelini, Giulia Paparella, Matteo Bologna","doi":"10.1080/14737175.2024.2372339","DOIUrl":"10.1080/14737175.2024.2372339","url":null,"abstract":"Introduction: Essential tremor (ET) and Parkinson's disease (PD) are the most common causes of tremor and the most prevalent movement disorders, with overlapping clinical features that can lead to diagnostic challenges, especially in the early stages.Areas covered: In the present paper, the authors review the clinical and experimental studies and emphasized the major aspects to differentiate between ET and PD, with particular attention to cardinal phenomenological features of these two conditions. Ancillary and experimental techniques, including neurophysiology, neuroimaging, fluid biomarker evaluation, and innovative methods, are also discussed for their role in differential diagnosis between ET and PD. Special attention is given to investigations and tools applicable in the early stages of the diseases, when the differential diagnosis between the two conditions is more challenging. Furthermore, the authors discuss knowledge gaps and unsolved issues in the field.Expert opinion: Distinguishing ET and PD is crucial for prognostic purposes and appropriate treatment. Additionally, accurate diagnosis is critical for optimizing clinical and experimental research on pathophysiology and innovative therapies. In a few years, integrated technologies could enable accurate, reliable diagnosis from early disease stages or prodromal stages in at-risk populations, but further research combining different techniques is needed.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"799-814"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mindfulness as a therapeutic option for obsessive-compulsive disorder. 将正念作为强迫症的一种治疗方法。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-06-18 DOI: 10.1080/14737175.2024.2365945

Andreas Reis, Marlon Westhoff, Hicham Quintarelli, Stefan G Hofmann

{"title":"Mindfulness as a therapeutic option for obsessive-compulsive disorder.","authors":"Andreas Reis, Marlon Westhoff, Hicham Quintarelli, Stefan G Hofmann","doi":"10.1080/14737175.2024.2365945","DOIUrl":"10.1080/14737175.2024.2365945","url":null,"abstract":"Introduction: Obsessive-compulsive disorder (OCD) is a prevalent mental health issue characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that can cause significant life impairment. Despite cognitive-behavioral therapy (CBT) being the most effective treatment, some individuals experience insufficient symptom reduction or relapse.Areas covered: This special report explores the potential of mindfulness-based interventions as complementary treatments for OCD, examining the specific techniques used and their practical application. In the initial section, the authors examine ten randomized control trial studies included in the meta-analysis conducted by Chien et al. (2022), demonstrating the effectiveness of mindfulness interventions. The authors focus on elucidating the specific mindfulness techniques used in these studies. Then, the authors discuss the integration of these mindfulness strategies into CBT, focusing on enhancing emotional regulation, cognitive flexibility, and acceptance of intrusive thoughts.Expert opinion: While mindful based interventions (MBIs) show promise as adjunctive treatments for OCD, variability in OCD symptoms and treatment responses necessitate individualized therapeutic approaches. Further research is required to refine mindfulness-based techniques and optimize their effectiveness. Incorporating MBIs into standard CBT protocols may improve outcomes for patients with persistent OCD symptoms.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"735-741"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on pharmacotherapy for trigeminal neuralgia. 三叉神经痛药物疗法的最新进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-06-13 DOI: 10.1080/14737175.2024.2365946

Joseph V Pergolizzi, Jo Ann LeQuang, Salah N El-Tallawy, Morgan Wagner, Rania S Ahmed, Giustino Varrassi

{"title":"An update on pharmacotherapy for trigeminal neuralgia.","authors":"Joseph V Pergolizzi, Jo Ann LeQuang, Salah N El-Tallawy, Morgan Wagner, Rania S Ahmed, Giustino Varrassi","doi":"10.1080/14737175.2024.2365946","DOIUrl":"10.1080/14737175.2024.2365946","url":null,"abstract":"Introduction: Trigeminal neuralgia is a rare condition that can be effectively treated by carbamazepine or oxcarbazepine but these older drugs are associated with dose-dependent and potentially treatment-limiting adverse effects. Third-generation anticonvulsants, new calcitonin gene-related peptide blockers for migraine, and older drugs such as ketamine and cannabinoids may be promising adjuvants or monotherapeutic options.Areas covered: The new drugs, their presumed mechanisms of action, safety and efficacy are discussed herein. There is a paucity of robust clinical evidence in support of these drugs for trigeminal neuralgia. New migraine agents are considered as well although migraines and trigeminal neuralgia are distinct, albeit similar, conditions. No new drugs have been released to market in recent years with the specific indication of trigeminal neuralgia.Expert opinion: In real-world clinical practice, about half of trigeminal neuralgia patients take more than one agent for prevention and combination therapy may be the optimal approach. Combination therapy might allow for lower doses of carbamazepine or oxcarbazepine, thus reducing the number and severity of potential adverse events but the potential for pharmacokinetic drug-drug interactions must be considered. Drug therapy for trigeminal neuralgia involves acute or abortive treatments, often administered in hospital versus long-term preventive therapy, usually involving oral agents.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"773-786"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder. 目前治疗成人注意力缺陷/多动症的非兴奋剂药物。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1080/14737175.2024.2370346

Giulio Emilio Brancati, Anna Magnesa, Donatella Acierno, Marco Carli, Ugo De Rosa, Alessandro Froli, Samuele Gemignani, Lisa Ventura, Francesco Weiss, Giulio Perugi

{"title":"Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder.","authors":"Giulio Emilio Brancati, Anna Magnesa, Donatella Acierno, Marco Carli, Ugo De Rosa, Alessandro Froli, Samuele Gemignani, Lisa Ventura, Francesco Weiss, Giulio Perugi","doi":"10.1080/14737175.2024.2370346","DOIUrl":"10.1080/14737175.2024.2370346","url":null,"abstract":"Introduction: Stimulants, including methylphenidate and amphetamines, are the first-line pharmacological treatment of ADHD in adults. However, in patients who do not respond or poorly tolerate stimulants, non-stimulant medications are usually recommended.Areas covered: The authors provide a narrative review of the literature on non-stimulant treatments for adult ADHD, including controlled and observational clinical studies conducted on adult samples. Atomoxetine has been extensively studied and showed significant efficacy in treating adult ADHD. Issues related to dosing, treatment duration, safety, and use in the case of psychiatric comorbidity are summarized. Among other compounds indicated for ADHD in adults, antidepressants sharing at least a noradrenergic or dopaminergic component, including tricyclic compounds, bupropion, and viloxazine, have shown demonstratable efficacy. Evidence is also available for antihypertensives, particularly guanfacine, as well as memantine, metadoxine, and mood stabilizers, while negative findings have emerged for galantamine, antipsychotics, and cannabinoids.Expert opinion: While according to clinical guidelines, atomoxetine may serve as the only second-line option in adults with ADHD, several other nonstimulant compounds may be effectively used in order to personalize treatment based on comorbid conditions and ADHD features. Nevertheless, further research is needed to identify and test more personalized treatment strategies for adults with ADHD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"743-759"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints. 617 名偏头痛患者对急性和预防性偏头痛治疗属性及临床试验终点的偏好和看法。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-06-13 DOI: 10.1080/14737175.2024.2365312

Michail Vikelis, Dimitrios Rikos, Andreas A Argyriou, Pinelopi Papachristou, Dimitrios Rallis, Theodoros Karapanayiotides, Andreas Galanopoulos, Konstantinos Spingos, Nikolaos Dimisianos, Emmanouil Giakoumakis, Periklis Zavridis, Konstantinos Notas, George S Vlachos, Panagiotis Soldatos, Konstantinos Bilias, Georgia Xiromerisiou, Jobst Rudolf, Emmanouil V Dermitzakis, Alan M Rapoport

{"title":"Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.","authors":"Michail Vikelis, Dimitrios Rikos, Andreas A Argyriou, Pinelopi Papachristou, Dimitrios Rallis, Theodoros Karapanayiotides, Andreas Galanopoulos, Konstantinos Spingos, Nikolaos Dimisianos, Emmanouil Giakoumakis, Periklis Zavridis, Konstantinos Notas, George S Vlachos, Panagiotis Soldatos, Konstantinos Bilias, Georgia Xiromerisiou, Jobst Rudolf, Emmanouil V Dermitzakis, Alan M Rapoport","doi":"10.1080/14737175.2024.2365312","DOIUrl":"10.1080/14737175.2024.2365312","url":null,"abstract":"Background: To identify the preferences and perceptions of migraine patients for acute and preventive treatment options and to investigate which treatment outcomes are the most important.Design and methods: The authors performed a choice-format survey in a cohort of migraine patients from Greece and Cyprus. A self-administered questionnaire developed in collaboration with the Greek Society of Migraine Patients was used.Results: Questionnaires were collected from 617 migraine patients. Efficacy was preferred over safety as the single most important parameter, both in acute and preventive treatment. When analyzing single outcomes, patients prioritized a complete pain remission at 1-hour post-dose for acute therapies. Regarding migraine prevention, a 75% reduction in frequency, intensity of pain, accompanying symptoms and acute medication intake were considered as most important. Conversely, outcomes routinely used in clinical trials, namely complete or partial pain remission at 2-hours post-dose for acute treatment and 50% or 30% reduction in migraine frequency for prevention, were not deemed particularly relevant. Tablet formulation was mostly preferred, both in acute and preventive treatment. Conclusion: Listening to patients' needs may add a piece of the puzzle that is generally missing in clinical practice and often explains the lack of adherence in both acute and preventative anti-migraine therapies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"815-826"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents. 概述布来匹唑治疗青少年精神分裂症的疗效和安全性。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/14737175.2024.2367695

Chesika J Crump, Hagar Abuelazm, Kirolos Ibrahim, Shaishav Shah, Rif S El-Mallakh

{"title":"An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents.","authors":"Chesika J Crump, Hagar Abuelazm, Kirolos Ibrahim, Shaishav Shah, Rif S El-Mallakh","doi":"10.1080/14737175.2024.2367695","DOIUrl":"10.1080/14737175.2024.2367695","url":null,"abstract":"Introduction: The onset of psychotic symptoms occurs prior to age 19 in 39% of the patients with schizophrenia. There are limited approved treatment options for adolescents with schizophrenia. Brexpiprazole was approved by the United States Food and Drug Administration (FDA) for treatment of schizophrenia in adolescents in 2022.Areas covered: Extrapolation of adult data to youth and use of pharmacologic modeling coupled with open long-term safety data were used by the FDA to approve brexpiprazole for adolescent schizophrenia. They were all reviewed herein.Expert opinion: D2 receptor partial agonist antipsychotic agents are preferred in the early phase of treatment of psychotic disorders. Approval of brexpiprazole in adolescent schizophrenia provides an additional option. Brexpiprazole was approved by the FDA on the basis of extrapolation of adult data without controlled trials in adolescents. This reduces placebo exposure in young people. Two previous agents (asenapine and ziprasidone) approved for adult schizophrenia failed to separate from placebo in adolescent schizophrenia studies; this partially undermines the process of extrapolation. For brexpiprazole, the paucity of data in adolescents relegates it to a second-line agent. More research on brexpiprazole is needed to delineate its relative role in the management of adolescent schizophrenia.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"727-733"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking the role of trazodone in the different depressive dimensions. 重新思考曲唑酮在不同抑郁维度中的作用。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-06-17 DOI: 10.1080/14737175.2024.2363843

Isabella Berardelli, Andrea Amerio, Francesco Bartoli, Alessandro Cuomo, Giacomo Deste, Laura Orsolini, Gaia Sampogna, Maurizio Pompili

{"title":"Rethinking the role of trazodone in the different depressive dimensions.","authors":"Isabella Berardelli, Andrea Amerio, Francesco Bartoli, Alessandro Cuomo, Giacomo Deste, Laura Orsolini, Gaia Sampogna, Maurizio Pompili","doi":"10.1080/14737175.2024.2363843","DOIUrl":"10.1080/14737175.2024.2363843","url":null,"abstract":"Introduction: The efficacy of trazodone for several psychopathologic dimensions of depression has been shown in the literature. Trazodone has been widely used in some clinical contexts (e.g. for insomnia and depression in the elderly). However, the role of trazodone in several aspects of depression is not well known.Area covered: Eight experts from academic and medical centers across Italy met to identify the difficulties and barriers faced in daily clinical practice in the assessment and management of major depressive disorder and how the use of trazodone could address some unmet needs. The objective of the expert meetings and the present document was to increase knowledge of particular areas of treatment with trazodone.Expert opinion: Evidence of the role of trazodone in patients affected by major depressive disorder with anxiety symptoms, insomnia, agitation, cognitive deficits, alcohol use disorders, physical comorbidities, and suicide risk has been identified, showing the effectiveness of trazodone in different presentations of major depressive disorder. The main characteristics of patients with depression for whom trazodone seems to be most effective have been identified, providing clinicians with information on possible uses of this drug in such population of patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"619-632"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in the treatment of dysthymia: a narrative review. 癔症治疗面临的挑战：叙述性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-05-28 DOI: 10.1080/14737175.2024.2360671

Livia Mathias, Laiana A Quagliato, Mauro G Carta, Antonio E Nardi, Elie Cheniaux

{"title":"Challenges in the treatment of dysthymia: a narrative review.","authors":"Livia Mathias, Laiana A Quagliato, Mauro G Carta, Antonio E Nardi, Elie Cheniaux","doi":"10.1080/14737175.2024.2360671","DOIUrl":"10.1080/14737175.2024.2360671","url":null,"abstract":"Introduction: Despite its milder severity, the chronic nature of dysthymia leads to significant impairments and functional limitations. The treatment of dysthymia has received considerably less research attention compared to major depressive disorder (MDD).Areas covered: The authors have conducted a comprehensive review on the treatment of dysthymia. Their primary objective was to identify therapeutic options that have demonstrated genuine efficacy. To do this, they searched the PubMed database, without any time restrictions, to retrieve original studies. The samples were exclusively comprised individuals diagnosed with dysthymia according to the diagnostic criteria outlined in DSM-III, DSM-III-R, DSM-IV, or DSM-IV-TR.Expert opinion: Within the realm of dysthymia treatment, several antidepressants, including imipramine, sertraline, paroxetine, minaprine, moclobemide, and amineptine, in addition to the antipsychotic agent amisulpride, have demonstrated superiority over placebo. In certain studies, psychotherapeutic interventions did not distinguish themselves significantly from pharmacological treatments and failed to exhibit greater efficacy than a placebo. However, these findings remain inconclusive due to the limited number of studies and substantial methodological limitations prevalent in a significant proportion of them. Limitations include factors like small sample sizes, the absence of placebo comparisons, and a lack of study blinding.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"633-642"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging protocols for non-traumatic spinal cord injury: current state of the art and future directions. 非创伤性脊髓损伤的成像方案：技术现状与未来方向。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-06-16 DOI: 10.1080/14737175.2024.2363839

Abdullah H Ishaque, Mohammed Ali Alvi, Karlo Pedro, Michael G Fehlings

{"title":"Imaging protocols for non-traumatic spinal cord injury: current state of the art and future directions.","authors":"Abdullah H Ishaque, Mohammed Ali Alvi, Karlo Pedro, Michael G Fehlings","doi":"10.1080/14737175.2024.2363839","DOIUrl":"10.1080/14737175.2024.2363839","url":null,"abstract":"Introduction: Non-traumatic spinal cord injury (NTSCI) is a term used to describe damage to the spinal cord from sources other than trauma. Neuroimaging techniques such as computerized tomography (CT) and magnetic resonance imaging (MRI) have improved our ability to diagnose and manage NTSCIs. Several practice guidelines utilize MRI in the diagnostic evaluation of traumatic and non-traumatic SCI to direct surgical intervention.Areas covered: The authors review practices surrounding the imaging of various causes of NTSCI as well as recent advances and future directions for the use of novel imaging modalities in this realm. The authors also present discussions around the use of simple radiographs and advanced MRI modalities in clinical settings, and briefly highlight areas of active research that seek to advance our understanding and improve patient care.Expert opinion: Although several obstacles must be overcome, it appears highly likely that novel quantitative imaging features and advancements in artificial intelligence (AI) as well as machine learning (ML) will revolutionize degenerative cervical myelopathy (DCM) care by providing earlier diagnosis, accurate localization, monitoring for deterioration and neurological recovery, outcome prediction, and standardized practice. Some intriguing findings in these areas have been published, including the identification of possible serum and cerebrospinal fluid biomarkers, which are currently in the early phases of translation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"691-709"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0